These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 26987078

  • 1. Effect of recombinant human erythropoietin and doxorubicin in combination on the proliferation of MCF-7 and MDA-MB231 breast cancer cells.
    Radwan EM, Abdullah R, Al-Qubaisi MS, El Zowalaty ME, Naadja SE, Alitheen NB, Omar AR.
    Mol Med Rep; 2016 May; 13(5):3945-52. PubMed ID: 26987078
    [Abstract] [Full Text] [Related]

  • 2. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
    Gewirtz DA, Di X, Walker TD, Sawyer ST.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2232-8. PubMed ID: 16609039
    [Abstract] [Full Text] [Related]

  • 3. Luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 human breast cancer cells.
    Sato Y, Sasaki N, Saito M, Endo N, Kugawa F, Ueno A.
    Biol Pharm Bull; 2015 Apr 01; 38(5):703-9. PubMed ID: 25947916
    [Abstract] [Full Text] [Related]

  • 4. Effects of Fucoidan and Chemotherapeutic Agent Combinations on Malignant and Non-malignant Breast Cell Lines.
    Abudabbus A, Badmus JA, Shalaweh S, Bauer R, Hiss D.
    Curr Pharm Biotechnol; 2017 Apr 01; 18(9):748-757. PubMed ID: 29141543
    [Abstract] [Full Text] [Related]

  • 5. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models.
    Hedley BD, Chu JE, Ormond DG, Beausoleil MS, Boasie A, Allan AL, Xenocostas A.
    Clin Cancer Res; 2011 Oct 01; 17(19):6151-62. PubMed ID: 21856770
    [Abstract] [Full Text] [Related]

  • 6. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, Chung HY, Kim HS.
    Biochim Biophys Acta; 2014 Jan 01; 1840(1):615-25. PubMed ID: 24161697
    [Abstract] [Full Text] [Related]

  • 7. Hippuric acid nanocomposite enhances doxorubicin and oxaliplatin-induced cytotoxicity in MDA-MB231, MCF-7 and Caco2 cell lines.
    Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Ismail M, Bullo S.
    Drug Des Devel Ther; 2013 Jan 01; 7():25-31. PubMed ID: 23345969
    [Abstract] [Full Text] [Related]

  • 8. Antiproliferative Activity of Combined Biochanin A and Ginsenoside Rh₂ on MDA-MB-231 and MCF-7 Human Breast Cancer Cells.
    Ren G, Shi Z, Teng C, Yao Y.
    Molecules; 2018 Nov 08; 23(11):. PubMed ID: 30413008
    [Abstract] [Full Text] [Related]

  • 9. (-)-Hinokinin Induces G2/M Arrest and Contributes to the Antiproliferative Effects of Doxorubicin in Breast Cancer Cells.
    Cunha NL, Teixeira GM, Martins TD, Souza AR, Oliveira PF, Símaro GV, Rezende KC, Gonçalves Ndos S, Souza DG, Tavares DC, Silva ML, Dos Santos RA.
    Planta Med; 2016 Apr 08; 82(6):530-8. PubMed ID: 27002393
    [Abstract] [Full Text] [Related]

  • 10. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
    Foroodi F, Duivenvoorden WC, Singh G.
    Anticancer Drugs; 2009 Feb 08; 20(2):115-22. PubMed ID: 19209028
    [Abstract] [Full Text] [Related]

  • 11. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
    Prados J, Melguizo C, Rama AR, Ortiz R, Segura A, Boulaiz H, Vélez C, Caba O, Ramos JL, Aránega A.
    Cancer Chemother Pharmacol; 2010 May 08; 66(1):69-78. PubMed ID: 19771430
    [Abstract] [Full Text] [Related]

  • 12. Effects and mechanism of recombinant human erythropoietin on the growth of human breast cancer MDA-MB-231 cells in nude mice.
    Jin W, Lin Z, Zhang X, Kong L, Yang L.
    Pathol Res Pract; 2015 Aug 08; 211(8):570-6. PubMed ID: 26008780
    [Abstract] [Full Text] [Related]

  • 13. Original research paper. Hydrazinyldiene-chroman-2,4-diones in inducing growth arrest and apoptosis in breast cancer cells: Synergism with doxorubicin and correlation with physicochemical properties.
    Ballazhi L, Imeri F, Jashari A, Popovski E, Stojković G, Dimovski AJ, Mikhova B, Mladenovska K.
    Acta Pharm; 2017 Mar 01; 67(1):35-52. PubMed ID: 28231049
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Growth factors and chemotherapeutic modulation of breast cancer cells.
    Ciftci K, Su J, Trovitch PB.
    J Pharm Pharmacol; 2003 Aug 01; 55(8):1135-41. PubMed ID: 12956904
    [Abstract] [Full Text] [Related]

  • 17. Effects of docetaxel, doxorubicin and cyclophosphamide on human breast cancer cell line MCF-7.
    Trebunova M, Laputkova G, Slaba E, Lacjakova K, Verebova A.
    Anticancer Res; 2012 Jul 01; 32(7):2849-54. PubMed ID: 22753747
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.
    Akbas SH, Timur M, Ozben T.
    J Surg Res; 2005 May 01; 125(1):49-55. PubMed ID: 15836850
    [Abstract] [Full Text] [Related]

  • 20. Doxorubicin and α-Mangostin oppositely affect luminal breast cancer cell stemness evaluated by a new retinaldehyde-dependent ALDH assay in MCF-7 tumor spheroids.
    Bissoli I, Muscari C.
    Biomed Pharmacother; 2020 Apr 01; 124():109927. PubMed ID: 31982725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.